Skip to main navigation Skip to search Skip to main content

Erratum: Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus⇓unrelated head and neck cancer: A multicenter, phase II trial (CLINICAL CANCER RESEARCH2020;26:5140–52 DOI: 10.1158/1078-0432.CCR-20-1695)

Research output: Contribution to journalComment/debate

Abstract

In the original version of this article (1), Fig. 4A and B were duplicated. Figure 4B has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

Original languageEnglish
Pages (from-to)357
Number of pages1
JournalClinical Cancer Research
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2021

Fingerprint

Dive into the research topics of 'Erratum: Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus⇓unrelated head and neck cancer: A multicenter, phase II trial (CLINICAL CANCER RESEARCH2020;26:5140–52 DOI: 10.1158/1078-0432.CCR-20-1695)'. Together they form a unique fingerprint.

Cite this